|
|
Article: Dr. Reddy's Q2 FY10 Results.
- Article from:
- Biotech Week
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dr. Reddy's Laboratories Ltd. (NYSE:RDY) announced its unaudited financial results for the second quarter ended September 30, 2009 under International Financial Reporting Standards (IFRS). Key Highlights Consolidated revenues at Rs. 18.4 billion ($382 million) in Q2 FY10 as against Rs. 16.2 billion ($336 million) in Q2 FY09, representing a growth of 14%. The growth is largely driven by Global Generics (see also Dr. Reddy's Laboratories Ltd.).
Consolidated revenues for H1 FY10 at Rs. 36.6 billion represent a YoY growth of 17%.
Sequentially, as compared to Q1 FY10, the revenues excluding sumatriptan have grown by 11%.
Operating income at Rs. 2.6 ...